[Hiring] Senior Regional Director, Field Based Medical Affairs @Karyopharm Therapeutics

Role Description

The Senior Regional Director, Field Based Medical Affairs is responsible for leading, developing, and managing a high-performing team of Medical Science Liaisons supporting the company’s solid tumor portfolio, with a primary focus on endometrial cancer as well as being an integral part of the GMSA LT. The Senior Director is responsible for cultivating, implementing, and managing scientific expertise and knowledge to ensure successful communication, education, and implementation of Karyopharm’s marketed and emerging product portfolio.

• Lead, manage, coach, and develop a team of field-based Medical Science Liaisons focused on solid tumors, with emphasis on endometrial cancer and gynecologic oncology.
• Provide strategic and tactical direction to ensure the MSL team executes against medical priorities, field medical plans, and broader organizational objectives.
• Establish clear performance expectations, goals, metrics, and development plans for direct reports.
• Active member of GMSA Leadership team.
• Contributor in cross-functional setting in close alignment with Karyopharm’s R&D and Commercial groups.
• Recruit, interview, hire, onboard, and retain highly qualified field medical talent.
• Support the professional development and career growth of MSL team members through coaching, mentoring, field observation, and regular performance feedback.
• Provide technical expertise to other members of the organization.
• Enhance cohesiveness among GMSA team members – providing a respectful, inclusive environment.
• Lead Congress planning and execution alongside GMSA Leadership and cross-functional partners.
• Proactively offer ideas and solutions to enhance the productivity of GMSA.
• Spearhead strategic initiatives.
• Deliver updates and presentations to senior leadership.
• Encourage best practices for the MSL team.
• Deliver scientific/clinical presentations as appropriate.
• Ensure representation of MSL team on select clinical/medical study teams.
• Take initiative and perform tasks in a self-directed manner.

Qualifications

• Minimum of 5 years previous MSL experience, preferably in gynecology oncology.
• Advanced degree in medical science (MD, PharmD, or PhD) required.
• Leadership experience (with direct reports or as an individual contributor) required.
• Strong project leadership and management history required.
• Ability to efficiently manage time and priorities.
• Strong leadership skills and the ability to compile and disseminate information to others in a cohesive fashion to assure a clear understanding of project status and direction.
• Solid understanding of drug development and life-cycle development of a product.
• Ability to cultivate and maintain relationships with thought leaders and to establish trust through the consistent demonstration of scientific expertise and satisfactory follow-through to requests from thought-leaders.
• Excellent communicator, skilled at diplomacy and capable of effectively combining science and relationship building.
• Ability to understand and translate external customer and/or internal client needs into effective decisions and to drive results and strive for continuous improvement with high performance in the face of adversity a must.
• Willingness to travel.

Benefits

• Comprehensive benefits (medical, dental, vision, 401(k), and more).
• Equity and the potential to receive annual target bonuses.
• Base salary range for this position is $240K - $280K USD.

Company Description

This is a uniquely exciting time to join Karyopharm Therapeutics where we are pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. We are building upon an established commercial foundation in multiple myeloma while advancing the potential of selinexor across additional hematologic and solid tumor cancers including myelofibrosis and TP53 wild-type endometrial cancer, areas where patients continue to face significant unmet needs.

• Our lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1) and is approved in the U.S. for adults with relapsed or refractory multiple myeloma, with approvals in more than 50 countries and territories outside the U.S.
• We are also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor.
• As we prepare for our next phase of growth, we are continuing to invest in critical capabilities across the organization to support future opportunities and deepen our impact in oncology.
• We are looking for talented people who are motivated by meaningful work, energized by growth and momentum, and excited by the opportunity to help shape what comes next in a collaborative, fast-moving environment where individual contributions are visible and valued.